6885 — BRIM Biotechnology Balance Sheet
0.000.00%
Last trade - 00:00- TWD4.37bn
- TWD2.71bn
- TWD0.02m
Annual balance sheet for BRIM Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 169 | 424 | 838 | 1,696 | 1,849 |
| Net Total Receivables | 0.63 | 0.37 | 0.448 | 6.24 | 10 |
| Prepaid Expenses | |||||
| Total Current Assets | 176 | 431 | 849 | 1,713 | 1,876 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.38 | 3.62 | 7.99 | 6.37 | 11.8 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 317 | 495 | 940 | 1,779 | 2,411 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 50.8 | 17.2 | 22.5 | 42 | 351 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 53.5 | 17.6 | 25.3 | 42.2 | 354 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 264 | 478 | 915 | 1,737 | 2,056 |
| Total Liabilities & Shareholders' Equity | 317 | 495 | 940 | 1,779 | 2,411 |
| Total Common Shares Outstanding |